Home › Compare › CYTH vs EPRT

CYTH vs EPRT: Dividend Comparison 2026

CYTH yields 277.55% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTH wins by $903.09M in total portfolio value
10 years
CYTH
CYTH
● Live price
277.55%
Share price
$0.72
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$903.15M
Annual income
$528,539,518.30
Full CYTH calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CYTH vs EPRT

📍 CYTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTHEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTH + EPRT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYTH pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTH
Annual income on $10K today (after 15% tax)
$23,591.45/yr
After 10yr DRIP, annual income (after tax)
$449,258,590.56/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CYTH beats the other by $449,247,675.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTH + EPRT for your $10,000?

CYTH: 50%EPRT: 50%
100% EPRT50/50100% CYTH
Portfolio after 10yr
$451.61M
Annual income
$264,276,179.51/yr
Blended yield
58.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CYTH
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Price Target
$0.95
+31.8% upside vs current
Range: $0.95 — $0.95
Altman Z
-45.6
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTH buys
0
EPRT buys
0
No recent congressional trades found for CYTH or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTHEPRT
Forward yield277.55% ✓3.92%
Annual dividend / share$2.00 ✓$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29% ✓
Portfolio after 10y$903.15M ✓$63.4K
Annual income after 10y$528,539,518.30 ✓$12,840.73
Total dividends collected$864.60M ✓$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$0.95$35.50 ✓

Year-by-year: CYTH vs EPRT ($10,000, DRIP)

YearCYTH PortfolioCYTH Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$38,455$27,754.65$11,205$505.18+$27.3K → CYTH
2$140,894$99,747.22$12,672$682.46+$128.2K → CYTH
3$492,311$341,554.29$14,490$930.48+$477.8K → CYTH
4$1,642,154$1,115,381.78$16,786$1,282.69+$1.63M → CYTH
5$5,234,184$3,477,078.74$19,753$1,791.56+$5.21M → CYTH
6$15,958,335$10,357,758.98$23,677$2,541.64+$15.93M → CYTH
7$46,588,915$29,513,496.29$29,008$3,672.99+$46.56M → CYTH
8$130,375,354$80,525,214.86$36,463$5,425.08+$130.34M → CYTH
9$350,102,914$210,601,285.35$47,238$8,221.57+$350.06M → CYTH
10$903,149,637$528,539,518.30$63,385$12,840.73+$903.09M → CYTH

CYTH vs EPRT: Complete Analysis 2026

CYTH — Stock

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Full CYTH Calculator →

EPRT — REIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CYTH vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTH vs SCHDCYTH vs JEPICYTH vs OCYTH vs KOCYTH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.